SPDR S&P Biotech (XBI) 128.25 $XBI
Shares of XBI Down 21.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 21, 11:17AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 2 month, SPDR S&P Biotech ETF has returned 21.15% as of today's recent price of $126.28.
1 of These 3 Cratering Biotechs is a Buy
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
At the start of the year, the theme seemed to be that biotech was in for another banner year, propelled by a suite of newly launch drugs that would go on to become blockbusters. These rosy prognostications were made despite broad-based biotech funds...
After Yesterday's Decline of 1.71%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Mon Apr 14, 4:02PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $119.06 to a high of $127.86. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $123.85 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biotech Is Officially in a Bear Market. Is It Time to Panic?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 3:03PM CDT
There was once a time when the biotech sector could do no wrong. Venture capital was literally coming up out of the floor to invest in the latest new development platforms. Secondary offerings were also being met with plenty of buyers. And let's not...
SPDR S&P Biotech ETF Shares Down 18.7% Since SmarTrend's Sell Call (XBI)
Comtex SmarTrend(R) - Fri Apr 11, 11:11AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 1 month, SPDR S&P Biotech ETF has returned 18.71% as of today's recent price of $130.19.
Jim Cramer's Mad Dash: HRB GILD
at The Street - Fri Apr 11, 9:38AM CDT
The tax man cometh and shows no sign of leaving, which means good news for H&R Block as it spins off its banking division, Cramer says.
Inside the Wild Ride of Biotech ETFs - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Apr 11, 9:01AM CDT
Biotech ETFs have been crashing, but have all the funds been performing the same in the space?
After Yesterday's Decline of 6.40%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Thu Apr 10, 5:14PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $128.38 to a high of $139.22. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of $129.76 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
'Fast Money' Recap: The Profit-Taking Spreads
at The Street - Tue Apr 08, 4:00AM CDT
The trading panel discussed how investors are selling all sorts of sectors, including steel and home improvement.
SPDR S&P Biotech ETF Down 12.4% Since SmarTrend Downtrend Call (XBI)
Comtex SmarTrend(R) - Fri Apr 04, 9:59AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 4 weeks, SPDR S&P Biotech ETF has returned 12.45% as of today's recent price of $140.22.
SmarTrend Watching for Potential Rebound in Shares of SPDR S&P Biotech ETF After 3.56% Loss
Comtex SmarTrend(R) - Thu Apr 03, 4:37PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $137.59 to a high of $144.94. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $138.06 on volume of 932,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Any Survivors from the Biotech ETF Meltdown? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 3:00PM CDT
Although all biotech ETFs crumbled last week, many might still be well positioned for the future.
3 ETFs to Watch as Obamacare Hits Deadline - ETF News And Commentary
Sweta Killa - ZACKS - Mon Mar 31, 1:00PM CDT
Expectation for a larger base of insurers under the Obamacare put these healthcare ETFs in focus for the coming weeks.
10.3% Return Seen to Date on SmarTrend SPDR S&P Biotech ETF Call (XBI)
Comtex SmarTrend(R) - Thu Mar 27, 10:05AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 3 weeks, SPDR S&P Biotech ETF has returned 10.29% as of today's recent price of $143.67.
SPDR S&P Biotech ETF Set to Possibly Rebound After Yesterday's Selloff of 3.25%
Comtex SmarTrend(R) - Wed Mar 26, 5:02PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $141.41 to a high of $148.38. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $142.63 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Cracks Beneath the Market's Surface
at The Street - Tue Mar 25, 10:45AM CDT
Even though the market has hit new highs, weakness lurks below. What should you do as an investor?
'Fast Money' Recap: The Value of 'Old Tech' Stocks
at The Street - Tue Mar 25, 4:00AM CDT
The trading panel discussed why these stocks have solid upside momentum and reasonable valuations.
Shares of XBI Down 21.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Apr 21, 11:17AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 2 month, SPDR S&P Biotech ETF has returned 21.15% as of today's recent price of $126.28.
1 of These 3 Cratering Biotechs is a Buy
George Budwell, The Motley Fool - Motley Fool - Fri Apr 18, 5:30PM CDT
At the start of the year, the theme seemed to be that biotech was in for another banner year, propelled by a suite of newly launch drugs that would go on to become blockbusters. These rosy prognostications were made despite broad-based biotech funds...
After Yesterday's Decline of 1.71%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Mon Apr 14, 4:02PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $119.06 to a high of $127.86. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $123.85 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biotech Is Officially in a Bear Market. Is It Time to Panic?
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 3:03PM CDT
There was once a time when the biotech sector could do no wrong. Venture capital was literally coming up out of the floor to invest in the latest new development platforms. Secondary offerings were also being met with plenty of buyers. And let's not...
SPDR S&P Biotech ETF Shares Down 18.7% Since SmarTrend's Sell Call (XBI)
Comtex SmarTrend(R) - Fri Apr 11, 11:11AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 1 month, SPDR S&P Biotech ETF has returned 18.71% as of today's recent price of $130.19.
Jim Cramer's Mad Dash: HRB GILD
at The Street - Fri Apr 11, 9:38AM CDT
The tax man cometh and shows no sign of leaving, which means good news for H&R Block as it spins off its banking division, Cramer says.
Inside the Wild Ride of Biotech ETFs - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Apr 11, 9:01AM CDT
Biotech ETFs have been crashing, but have all the funds been performing the same in the space?
After Yesterday's Decline of 6.40%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Thu Apr 10, 5:14PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $128.38 to a high of $139.22. Yesterday, the shares fell 6.4%, which took the trading range below the 3-day low of $129.76 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
'Fast Money' Recap: The Profit-Taking Spreads
at The Street - Tue Apr 08, 4:00AM CDT
The trading panel discussed how investors are selling all sorts of sectors, including steel and home improvement.
SPDR S&P Biotech ETF Down 12.4% Since SmarTrend Downtrend Call (XBI)
Comtex SmarTrend(R) - Fri Apr 04, 9:59AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 4 weeks, SPDR S&P Biotech ETF has returned 12.45% as of today's recent price of $140.22.
SmarTrend Watching for Potential Rebound in Shares of SPDR S&P Biotech ETF After 3.56% Loss
Comtex SmarTrend(R) - Thu Apr 03, 4:37PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $137.59 to a high of $144.94. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $138.06 on volume of 932,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Any Survivors from the Biotech ETF Meltdown? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Mon Mar 31, 3:00PM CDT
Although all biotech ETFs crumbled last week, many might still be well positioned for the future.
3 ETFs to Watch as Obamacare Hits Deadline - ETF News And Commentary
Sweta Killa - ZACKS - Mon Mar 31, 1:00PM CDT
Expectation for a larger base of insurers under the Obamacare put these healthcare ETFs in focus for the coming weeks.
10.3% Return Seen to Date on SmarTrend SPDR S&P Biotech ETF Call (XBI)
Comtex SmarTrend(R) - Thu Mar 27, 10:05AM CDT
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on March 7th, 2014 at $160.16. In approximately 3 weeks, SPDR S&P Biotech ETF has returned 10.29% as of today's recent price of $143.67.
SPDR S&P Biotech ETF Set to Possibly Rebound After Yesterday's Selloff of 3.25%
Comtex SmarTrend(R) - Wed Mar 26, 5:02PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $141.41 to a high of $148.38. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $142.63 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Cracks Beneath the Market's Surface
at The Street - Tue Mar 25, 10:45AM CDT
Even though the market has hit new highs, weakness lurks below. What should you do as an investor?
'Fast Money' Recap: The Value of 'Old Tech' Stocks
at The Street - Tue Mar 25, 4:00AM CDT
The trading panel discussed why these stocks have solid upside momentum and reasonable valuations.
